MARKET

NNVC

NNVC

Nanoviricides
AMEX
2.450
-0.860
-25.98%
Closed 19:53 06/12 EDT
OPEN
3.350
PREV CLOSE
3.310
HIGH
3.350
LOW
2.360
VOLUME
748.08K
TURNOVER
0
52 WEEK HIGH
3.590
52 WEEK LOW
1.000
MARKET CAP
28.94M
P/E (TTM)
-3.0191
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Wednesday's Intraday Session
Longeveron (NASDAQ:LGVN) shares rose 112.1% to $1.74 during Wednesday's regular session. VTv Therapeutics stock increased by 43.09% to $26.0. Avidity Biosciences shares increased by 32.32% during the session. ThermoGenesis Holdings shares fell 31.4% in the same session.
Benzinga · 17h ago
NanoViricides' NV-387 Results Show Flat Blood Concentration Profile For Prolonged Antiviral Effect In Clinical Trials
Benzinga · 1d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Seres Therapeutics stock moved upwards by 34.0% to $0.82 during Monday's regular session. Renovaro (NASDAQ:RENB) shares increased by 32.51%. Champions Oncology stock increased by 22.82%. Novavax stock decreased by 14.62%.
Benzinga · 2d ago
Weekly Report: what happened at NNVC last week (0603-0607)?
Weekly Report · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investorplace · 6d ago
12 Health Care Stocks Moving In Wednesday's After-Market Session
Anitra shares increased by 6.5% to $0.18 during Wednesday's after-market session. PACS Group (NYSE:PACS) shares rose 3.95% during the session. Oragenics (AMEX:OGEN) shares moved upwards by 4.24%. Losers include Concord Medical Services and Theriva Biologics.
Benzinga · 06/05 20:31
12 Health Care Stocks Moving In Tuesday's After-Market Session
Concord Medical Services (NYSE:CCM) shares moved upwards by 131.0% to $4.85 during Tuesday's after-market session. The company's market cap stands at $210.6 million. MAIA Biotechnology (AMEX:MAIA) and Emergent BioSolutions (NYSE) also moved upwards.
Benzinga · 06/04 20:31
NanoViricides Reports On The Highly Desirable Blood Concentration Profile Of Its Lead Clinical Stage Broad-spectrum Antiviral Agent NV-387 Upon Intravenous Administration In A Non-human Primate Animal Model
Lead nanoviricide broad-spectrum antiviral drug candidate NV-387 found to have a flat plateau of blood concentration over 24 hours in a monkey model. Company says the drug increased in a dose-dependent manner in a 24-hour period in the monkeys.
Benzinga · 06/04 11:03
More
About NNVC
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.

Webull offers NanoViricides Inc stock information, including AMEX: NNVC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NNVC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NNVC stock methods without spending real money on the virtual paper trading platform.